mRNA Cancer Vaccines in August 2026: It's Not a Drug, It's a Pipeline
On August 19, Moderna and Merck announced that intismeran autogene had hit its primary and key secondary endpoints in the INTerpath-001 Phase 3 melanoma trial (1,137 patients) — the first-ever positive Phase 3 result for a personalized mRNA cancer therapy ( Merck press release, 2…
Read more →